利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

7 条记录 (耗时 0.015 秒)

    Tamoxifen derivatives for treatment of neoplastic diseases, especially with high HER2 protein level
    2.
    发明授权
    Tamoxifen derivatives for treatment of neoplastic diseases, especially with high HER2 protein level 有权

    公开(公告)号：US09896466B2

    公开(公告)日：2018-02-20

    申请号：US14786710

    申请日：2014-04-07

    申请人： Smart Brain S.R.O. ,  Biotechnologicky Ustav Av Cr, V.V.I. ,  Jiri Neuzil ,  KKCG AG

    发明人： Jiri Neuzil ,  Jan Stursa ,  Lukas Werner

    IPC分类号： C07F9/54 ,  A61K31/135

    CPC分类号： C07F9/5456 ,  C07F9/5442 ,  C07F9/5449

    摘要： The subject of the invention are new mitochondrially targeted E/Z isomers of aliphatic triphenylphosphonium derivatives of tamoxifen where the aliphatic chain is alkyl or alkenyl, and their corresponding tertiary amine salts and/or their mixture (MitoTAX). Alkyl triphenylphosphonium derivatives of tamoxifen have the general formula (I), where n=8 to 12 and where Z is selected from the group of organic salts or inorganic salts. Alkenyl triphenylphosphonium derivatives of tamoxifen have the general formula IA, where n=6 to 10 and where Z has the above mentioned meaning. These compounds are applicable for the treatment of neoplastic disease, especially those with high HER2 protein levels. The drug for the treatment of neoplastic diseases according to the invention contains at least one E/Z isomer of aliphatic triphenylphosphonium derivatives of tamoxifen of the general formula (I) and/or IA or their corresponding salts of tertiary amine.

    PSMA-specific binding proteins
    6.
    发明授权
    PSMA-specific binding proteins 有权

    公开(公告)号：US11464877B2

    公开(公告)日：2022-10-11

    申请号：US16514899

    申请日：2019-07-17

    申请人： TECHNISCHE UNIVERSITÄT MÜNCHEN ,  BIOTECHNOLOGICKY USTAV AV CR, V.V.I.

    发明人： Arne Skerra ,  Antonia Richter ,  Volker Morath ,  Cyril Barinka ,  Jakub Ptacek

    IPC分类号： A61K38/17 ,  A61K49/00 ,  C07K14/47 ,  C07K7/06 ,  C07K7/08 ,  C07K14/705 ,  C07K19/00 ,  C12N15/62 ,  G01N33/533 ,  G01N33/574

    摘要： The present invention relates to a prostate-specific membrane antigen (PSMA)-specific binding protein, wherein the PSMA-specific binding protein is a lipocalin 2 (Lcn2)-derived binding protein and binds to PSMA with a KD of 10 nM or lower. The present invention also relates to a nucleic acid molecule encoding the PSMA-specific binding protein of the invention, a vector comprising said nucleic acid molecule of the invention and a host cell transformed with the vector. Furthermore, the invention relates to a method of producing the PSMA-specific binding protein of the invention, the method comprising culturing the host cell of the invention under suitable conditions and isolating the PSMA-specific binding protein produced. The present invention further relates to a protein conjugate comprising the PSMA-specific binding protein of the invention, or the PSMA-specific binding protein produced by the method of the invention. In addition, the present invention relates to a pharmaceutical or diagnostic composition; to the PSMA-specific binding protein of the invention, the nucleic acid molecule of the invention, the vector of the invention, the host cell of the invention or the PSMA-specific binding protein produced by the method of the invention, for use in therapy and/or diagnosis, and in particular for use in the therapy and/or diagnosis of tumors, Crohn's disease and/or neurological diseases.